You're asking about a specific chemical compound, **2-(3-acetyl-1-indolyl)-N-(2,4-dimethylphenyl)acetamide**. This compound doesn't have a widely recognized name or a readily available research history.
Let's break down the components and why it *could* be of interest to research:
**Components of the Compound:**
* **Indole:** A core structure found in many biologically active compounds, including the neurotransmitter serotonin.
* **Acetyl:** A common functional group involved in various biochemical reactions.
* **Acetamide:** Another common functional group often found in pharmaceuticals.
* **2,4-dimethylphenyl:** A substituted phenyl ring, which can influence a molecule's properties.
**Possible Research Relevance:**
* **Pharmaceutical Development:** The combination of these components suggests that this compound could have potential pharmacological activity. Indole-based compounds are often explored for their impact on the central nervous system, while acetamide groups are frequently found in pain relievers and anti-inflammatory drugs.
* **Biological Activity:** This compound might interact with specific enzymes or receptors in the body. It could have effects on cell signaling, neurotransmission, or even influence the development of new drugs.
**Why it's Difficult to Find Research:**
* **New Compound:** This specific compound might be newly synthesized. It could be part of a research project currently underway, and the results might not be publicly available yet.
* **Limited Research:** Even if it's been studied, it might have shown limited activity or undesirable side effects, making it less attractive for further investigation.
**Finding More Information:**
To learn more, you would need to do the following:
1. **Check Chemical Databases:** Search for the compound's name or structure in chemical databases like PubChem, SciFinder, or Reaxys.
2. **Search Scientific Literature:** Use search engines like Google Scholar or PubMed with keywords like 2-(3-acetyl-1-indolyl)-N-(2,4-dimethylphenyl)acetamide or related terms like indole derivatives or acetamide derivatives.
3. **Contact Research Groups:** If you find research papers related to this compound or similar structures, you can try to contact the researchers involved directly.
Remember that scientific research takes time, and not all compounds are extensively studied. It's possible this compound might be a promising lead for future research, but it's also possible it might not be of major interest due to lack of activity or other factors.
ID Source | ID |
---|---|
PubMed CID | 1088499 |
CHEMBL ID | 1453704 |
CHEBI ID | 113121 |
Synonym |
---|
MLS000528237 , |
smr000120812 |
2-(3-acetyl-indol-1-yl)-n-(2,4-dimethyl-phenyl)-acetamide |
CHEBI:113121 |
AKOS000465391 |
2-(3-acetylindol-1-yl)-n-(2,4-dimethylphenyl)acetamide |
HMS2177J22 |
STL431616 |
2-(3-acetyl-1h-indol-1-yl)-n-(2,4-dimethylphenyl)acetamide |
CHEMBL1453704 |
SR-01000365593-1 |
sr-01000365593 |
2-(3-acetyl-1-indolyl)-n-(2,4-dimethylphenyl)acetamide |
Q27193585 |
Class | Description |
---|---|
indoles | Any compound containing an indole skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 1.5849 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 1.8356 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 5.4892 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
67.9K protein | Vaccinia virus | Potency | 1.4125 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 23.1093 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 7.0795 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
DNA polymerase beta | Homo sapiens (human) | Potency | 79.4328 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.1623 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 18.1695 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 6.3096 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 3.1623 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |